tiprankstipranks
Blurbs

Analysts’ Top Healthcare Picks: VYNE Therapeutics (VYNE), Gilead Sciences (GILD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on VYNE Therapeutics (VYNEResearch Report), Gilead Sciences (GILDResearch Report) and KalVista Pharmaceuticals (KALVResearch Report) with bullish sentiments.

VYNE Therapeutics (VYNE)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on VYNE Therapeutics today and set a price target of $7.00. The company’s shares closed last Monday at $0.50, close to its 52-week low of $0.46.

According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -22.8% and a 21.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

VYNE Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $8.50.

See today’s best-performing stocks on TipRanks >>

Gilead Sciences (GILD)

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Gilead Sciences, with a price target of $75.00. The company’s shares closed last Monday at $62.02.

According to TipRanks.com, Syed is ranked 0 out of 5 stars with an average return of -15.9% and a 35.0% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Coherus Biosciences, and Unity Biotechnology.

Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $73.13, representing a 24.0% upside. In a report issued on February 21, Jefferies also maintained a Buy rating on the stock with a $80.00 price target.

KalVista Pharmaceuticals (KALV)

In a report released today, Serge Belanger from Needham maintained a Buy rating on KalVista Pharmaceuticals, with a price target of $48.00. The company’s shares closed last Monday at $15.67.

According to TipRanks.com, Belanger is a 3-star analyst with an average return of 2.8% and a 42.6% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Phasebio Pharmaceuticals, and Verrica Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for KalVista Pharmaceuticals with a $49.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VYNE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed